NCT04642651 is a Phase 4 clinical trial of Dexmedetomidine in Elderly, sponsored by Peking University First Hospital.

Who is sponsoring NCT04642651?

NCT04642651 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT04642651?

Interventions in NCT04642651: Dexmedetomidine, Placebo.

What condition does NCT04642651 study?

NCT04642651 studies Elderly, Total Knee Arthroplasty, Femoral Nerve Block, Dexmedetomidine, Functional Outcome.

Is NCT04642651 still recruiting?

NCT04642651 is currently completed. Last updated 20 April 2022.

Last reviewed 2022-04-20 · How we verify

NCT04642651

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine as an Adjuvant for Femoral Nerve Block and Functional Recovery After Total Knee Arthroplasty

Completed Phase 4 Last updated 20 April 2022

What this trial tests

Phase 4 trial testing Dexmedetomidine in Elderly in 170 participants. Completed in 25 February 2022.

Timeline

25 November 2020

Primary endpoint
22 November 2021

25 February 2022

Quick facts

Lead sponsor	Peking University First Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	170
Start date	25 November 2020
Primary completion	22 November 2021
Estimated completion	25 February 2022
Sites	2 locations across China

Drugs / interventions tested

Dexmedetomidine (dexmedetomidine) — full drug profile →
Placebo

Conditions studied

Elderly — all drugs for Elderly →
Total Knee Arthroplasty — all drugs for Total Knee Arthroplasty →
Femoral Nerve Block — all drugs for Femoral Nerve Block →
Dexmedetomidine — all drugs for Dexmedetomidine →

Sponsor

Peking University First Hospital

Who can join

Adults 65 to 89, any sex, with Elderly or Total Knee Arthroplasty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Femoral nerve block (FNB) is a first-line analgesic technique for multimodal analgesia after total knee arthroplasty (TKA). Recent studies and meta-analysis indicate that dexmedetomidine combined with local anesthetics for FNB can prolong the analgesic duration, improve the analgesic efficacy, inhibit local inflammatory response, and reduce narcotic consumption. The investigators hypothesize that dexmedetomidine combined with ropivacaine for FNB can also improve functional recovery in aged patients after TKA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting

Other recruiting trials for Elderly

Currently open trials in the same condition.

NCT07494110 — Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations · NA · recruiting
NCT07479147 — SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07309965 — Feasibility of Integrating Local Vibration Into Rehabilitation of Elderly Patients After Hip Fracture · NA · recruiting
NCT07521189 — Effect of Vegetarien Diet on Protein Digestibility in Young and Elderly Volunteers · NA · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04642651 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 20 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04642651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing